Cutler Group LP Incyte Corp Put Options Transaction History

Cutler Group LP

11 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2022 Apr 14, 2022	SELL	$66.02 - $79.71 $52,816 - $63,767	-800 Reduced 22.86%	2,700 $3,000
Q4 2021 Jan 18, 2022	SELL	$63.34 - $74.11 $114,012 - $133,398	-1,800 Reduced 33.96%	3,500 $17,000
Q3 2021 Oct 26, 2021	BUY	$68.67 - $84.02 $226,611 - $277,266	3,300 Added 165.0%	5,300 $11,000
Q3 2020 Oct 27, 2020	SELL	$85.07 - $109.69 $255,209 - $329,070	-3,000 Reduced 60.0%	2,000 $1,000
Q1 2019 May 10, 2019	SELL	$63.56 - $88.17 $3.99 Million - $5.54 Million	-62,800 Reduced 92.63%	5,000 $27,000
Q4 2018 Feb 05, 2019	BUY	$58.5 - $69.94 $473,850 - $566,514	8,100 Added 13.57%	67,800 $207,000
Q3 2018 Nov 07, 2018	SELL	$61.75 - $74.23 $61,750 - $74,230	-1,000 Reduced 1.65%	59,700 $321,000
Q2 2018 Aug 10, 2018	BUY	$60.85 - $83.98 $1.53 Million - $2.11 Million	25,100 Added 70.51%	60,700 $389,000
Q1 2018 May 11, 2018	SELL	$83.06 - $100.98 $4.24 Million - $5.15 Million	-51,000 Reduced 58.89%	35,600 $761,000
Q4 2017 Jan 17, 2018	BUY	$93.56 - $116.6 $2.98 Million - $3.72 Million	31,900 Added 58.32%	86,600 $1.2 Million
Q3 2017 Oct 17, 2017	BUY	$109.15 - $138.27 $5.97 Million - $7.56 Million	54,700	54,700 $617,000

644

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16.6B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.